Comment on FDA's Breakthrough Therapy Designation of Intranasal Esketamine for the Treatment of Major Depressive Disorder with Imminent Risk of Suicide
- DOI
- 10.5455/bcp.20161027122045
- Published
- 2016-12
- Container
- Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology
- Publisher
- Informa UK Limited
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.5455/bcp.20161027122045,
title = {Comment on FDA's Breakthrough Therapy Designation of Intranasal Esketamine for the Treatment of Major Depressive Disorder with Imminent Risk of Suicide},
author = {Reji Thomas and Mesut Cetin and Glen B. Baker and Serdar M. Dursun},
year = {2016},
journal = {Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology},
doi = {10.5455/bcp.20161027122045},
url = {https://doi.org/10.5455/bcp.20161027122045}
}RIS
TY - JOUR TI - Comment on FDA's Breakthrough Therapy Designation of Intranasal Esketamine for the Treatment of Major Depressive Disorder with Imminent Risk of Suicide AU - Reji Thomas AU - Mesut Cetin AU - Glen B. Baker AU - Serdar M. Dursun PY - 2016 JO - Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology DO - 10.5455/bcp.20161027122045 UR - https://doi.org/10.5455/bcp.20161027122045 ER -
APA
Thomas, R., Cetin, M., Baker, G. B., & Dursun, S. M. (2016). Comment on FDA's Breakthrough Therapy Designation of Intranasal Esketamine for the Treatment of Major Depressive Disorder with Imminent Risk of Suicide. Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology. https://doi.org/10.5455/bcp.20161027122045
Source records
- crossref · retrieved 2026-11-10T04:55:32.773Z